96. Crohn disease Clinical trials / Disease details

Clinical trials : 2,442 / Drugs : 1,278 - (DrugBank : 248) / Drug target genes : 142 - Drug target pathways : 209

diseases per page:

Showing 1 to 10 of 2,442 diseases

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT05509777 (ClinicalTrials.gov)	August 1, 2023	19/8/2022	A Study of Mirikizumab (LY3074828) in Pediatric Participants With Crohn's Disease (AMAY)	A Phase 3, Multicenter, Randomized Clinical Study to Evaluate Mirikizumab in Pediatric Crohn's Disea ...	Crohn's Disease	Drug: Mirikizumab	Eli Lilly and Company	NULL	Not yet recruiting	2 Years	17 Years	All	90	Phase 3	NULL
2	NCT05471492 (ClinicalTrials.gov)	July 30, 2023	18/7/2022	Study to Evaluate the Efficacy and Safety of PF-06480605 in Adult Participants With Moderate to Seve ...	A PHASE 2A, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY WITH AN OPEN LABEL CHRON ...	Crohn Disease	Drug: Investigational Product;Drug: Placebo	Pfizer	NULL	Not yet recruiting	18 Years	75 Years	All	164	Phase 2	NULL
3	NCT05442567 (ClinicalTrials.gov)	May 2, 2023	30/6/2022	A Study of Vedolizumab in Pediatric Participants With Ulcerative Colitis (UC) or Crohn's Disease(CD) ...	A Phase 3b Extension Study to Evaluate the Long-term Safety of Vedolizumab Intravenous in Pediatric ...	Ulcerative Colitis;Crohn's Disease	Drug: Vedolizumab IV;Other: No Intervention	Takeda	NULL	Not yet recruiting	3 Years	17 Years	All	240	Phase 3	NULL
4	NCT05584228 (ClinicalTrials.gov)	April 1, 2023	26/9/2022	Medical Treatment Versus Surgery in Stricturing Small Bowel Crohn's Disease	SyMptomAtic Stricturing Small Bowel CRohn's Disease- Medical Treatment Versus Surgery, a Prospective ...	Crohn Disease	Drug: Azathioprine + infliximab;Procedure: Intestinal resection	Nantes University Hospital	Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives	Not yet recruiting	18 Years	70 Years	All	150	N/A	NULL
5	NCT05660746 (ClinicalTrials.gov)	April 1, 2023	29/11/2022	Precise Infliximab Exposure and Pharmacodynamic Control	Precise Infliximab Exposure and Pharmacodynamic Control to Achieve Deep Remission in Pediatric Crohn ...	Crohn Disease	Device: RoadMAB;Drug: Infliximab	Children's Hospital Medical Center, Cincinnati	National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK);Janssen Scientific Affairs, ...	Not yet recruiting	6 Years	22 Years	All	180	Phase 2/Phase 3	United States
6	NCT05470985 (ClinicalTrials.gov)	March 10, 2023	12/7/2022	A Study to Evaluate the Efficacy, Safety, and Drug Levels of Oral Ozanimod in Pediatric Participants ...	A Phase 2/3, Multicenter, Randomized, Double-blind Study to Evaluate the Efficacy, Safety, Pharmacok ...	Crohn Disease	Drug: Ozanimod	Bristol-Myers Squibb	NULL	Recruiting	2 Years	17 Years	All	120	Phase 2/Phase 3	United States;Australia;Belgium;Canada;Hungary;Poland;Spain;United Kingdom
7	NCT05659953 (ClinicalTrials.gov)	March 1, 2023	25/11/2022	LMT503 First-in-human SAD, MAD, and FE Study	A Phase 1, Randomized, Double-blind, Placebo-controlled, Single Ascending Dose, Multiple Ascending D ...	Colitis, Ulcerative;Crohn Disease;Inflammatory Bowel Disease	Drug: LMT503;Drug: Placebo	Lmito Therapeutics Inc.	NULL	Not yet recruiting	18 Years	65 Years	All	72	Phase 1	Netherlands
8	NCT05552287 (ClinicalTrials.gov)	March 2023	11/7/2022	Pharmacokinetic Infliximab Data in Pediatric Crohn's Disease	Prospective Analysis of Pharmacokinetic Infliximab Data in Pediatric CD Patients (ProRAPID)	Crohn Disease;Child, Only;Biologic; Inadequate	Drug: Infliximab	Erasmus Medical Center	NULL	Not yet recruiting	3 Years	15 Years	All	50	Phase 4	NULL
9	NCT05705856 (ClinicalTrials.gov)	February 15, 2023	15/1/2023	Effectiveness and Safety of Ustekinumab Intensification in Crohn's Disease	Effectiveness and Safety of Ustekinumab Intensification in Crohn's Disease: a Retrospective Observat ...	Crohn Disease	Drug: Ustekinumab	Second Affiliated Hospital, School of Medicine, Zhejiang University	NULL	Not yet recruiting	18 Years	N/A	All	200		NULL
10	NCT03992469 (ClinicalTrials.gov)	February 15, 2023	18/6/2019	Study to Evaluate Safety, Tolerability and Efficacy of Oral E-B-FAHF-2 in Mild-to-Moderate Crohn's D ...	Study to Evaluate Safety, Tolerability, and Early Efficacy of Oral E-B-FAHF-2 in Subjects With Mild- ...	Crohn's Disease	Drug: EBFAHF-2;Drug: Placebo	Icahn School of Medicine at Mount Sinai	NULL	Recruiting	18 Years	30 Years	All	28	Phase 1	United States

First Previous1 2 3 4 5…245Next Last